Camber Launches Eltrombopag PFOS & Tablets

Camber Pharmaceuticals is proud to announce the launch of Eltrombopag, the AB Rated generic for Promacta®.

Through Camber’s copayment program, eligible patients may pay as little as $0 out-of-pocket. Visit Camber’s Eltrombopag web page for full offer details.

“For years, many patients have struggled to afford this life-saving therapy,” said Kon Ostaficiuk, President of Camber Pharmaceuticals. “We are excited to offer this important medication with a copay assistance program.”

Eltrombopag is indicated for thrombocytopenia—a serious condition affecting platelet counts—and for aplastic anemia, a condition that impacts the production of new blood cells.

A summary ofEltrombopag’s indications (Oral Suspension and Tablets) appears below:

• Persistent or chronic Immune Thrombocytopenia (ITP) in all patients 1 year and older insufficiently responsive to other treatments and only in patients with increased risk of bleeding
• Thrombocytopenia only in chronic hepatitis C patients whose clinical condition prevents or limits initiation/maintenance of interferon-based therapy
• Patients with severe aplastic anemia who are insufficiently responsive to immunosuppressive therapy
• Visit www.CamberEltrombopag.com for full indications and product details.

Dosage Availability:

1. Camber’s Eltrombopag for Oral Suspension is available in cartons of 30 unit-dose packets in 12.5 mg and 25 mg strengths.
2. Camber’s Eltrombopag Tablets are available in 30-count bottles in 12.5 mg, 25 mg, 50 mg, and 75 mg strengths.

To learn more about Camber’s Eltrombopag—the AB Rated generic for Promacta®—please visit www.CamberEltrombopag.com or contact your Camber representative.

Promacta® is a registered trademark of Novartis Pharma AG. Camber is not affiliated with Novartis.